biOasis Enters Into a Research & Evaluation Agreement with 91) ?
biOasis Enters Into a Research & Evaluation Agreement with MedImmune
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/14/12 -- biOasis
Technologies Inc. (TSX VENTURE:BTI) announced today that it has
entered into a research and evaluation agreement with MedImmune
(MedImmune), the global biologics arm of AstraZeneca. Under the terms
of this collaboration, biOasis will conduct certain experiments at
MedImmune's expense with the objective of demonstrating that
biOasis's Transcend technology can deliver to the brain compounds of
interest to MedImmune.
"biOasis is very pleased to enter this collaboration with MedImmune
who are leaders in the development of biologics," said Rob Hutchison,
CEO of biOasis. "The work we have done to date on Transcend and the
milestones we have achieved all support driving us to agreements such
as the one we are announcing today. We look forward to working with
MedImmune to successfully achieve the objectives set out in agreement.